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most common cause of autosomal dominant optic atrophy. However, the frequency of these syndromal ‘dominant optic atrophy
plus’ variants and the extent of neurological involvement have not been established. In this large multi-centre study of 104
patients from 45 independent families, including 60 new cases, we show that extra-ocular neurological complications are
common in OPA1 disease, and affect up to 20% of all mutational carriers. Bilateral sensorineural deafness beginning in late
childhood and early adulthood was a prominent manifestation, followed by a combination of ataxia, myopathy, peripheral
neuropathy and progressive external ophthalmoplegia from the third decade of life onwards. We also identiﬁed novel clinical
presentations with spastic paraparesis mimicking hereditary spastic paraplegia, and a multiple sclerosis-like illness. In contrast
to initial reports, multi-system neurological disease was associated with all mutational subtypes, although there was an
increased risk with missense mutations [odds ratio=3.06, 95% conﬁdence interval=1.44–6.49; P=0.0027], and mutations
located within the guanosine triphosphate-ase region (odds ratio=2.29, 95% conﬁdence interval=1.08–4.82; P=0.0271).
Histochemical and molecular characterization of skeletal muscle biopsies revealed the presence of cytochrome c oxidase-
deﬁcient ﬁbres and multiple mitochondrial DNA deletions in the majority of patients harbouring OPA1 mutations, even in
those with isolated optic nerve involvement. However, the cytochrome c oxidase-deﬁcient load was over four times higher in the
dominant optic atrophy+group compared to the pure optic neuropathy group, implicating a causal role for these secondary
mitochondrial DNA defects in disease pathophysiology. Individuals with dominant optic atrophy plus phenotypes also had
signiﬁcantly worse visual outcomes, and careful surveillance is therefore mandatory to optimize the detection and management
of neurological disability in a group of patients who already have signiﬁcant visual impairment.
Keywords: deletions; dominant optic atrophy; hereditary spastic paraplegia; mitochondrial DNA; multiple sclerosis; OPA1
Abbreviations: COX = cytochrome c oxidase; DOA = autosomal dominant optic atrophy; DOA+=dominant optic atrophy plus
syndrome; GTP=Guanosine triphosphate; LogMAR = logarithm of the minimum angle of resolution; mtDNA = mitochondrial DNA;
PCR = polymerase chain reaction; SDH = succinate dehydrogenase
Introduction
Mitochondria supply most of the cellular adenosine triphosphate
(ATP) requirements through oxidative phosphorylation, a process
that involves ﬁve protein complexes located along the inner mito-
chondrial membrane. Mitochondrial DNA (mtDNA) codes for 13 of
the key structural polypeptides that constitute these multimeric
complexes, in addition to two ribosomal RNAs and 22 transfer
RNAs which are required for initiating translation and protein syn-
thesis (DiMauro and Schon, 2003; Schapira, 2006). Over the past
decade, a growing number of nuclear genetic defects have been
identiﬁed that disrupt mitochondrial function either by a reduction
in mtDNA copy number, and/or the accumulation of secondary
mtDNA deletions: POLG1, POLG2, PEO1, SLC25A4, TYMP,
DGUOK, TK2, SUCLA2, SUCLG1, MPV17 and RRM2B (Hudson
and Chinnery, 2006; Chinnery and Zeviani, 2008; Copeland,
2008). These disorders of mtDNA maintenance constitute an impor-
tant group of human genetic diseases and they manifest as an array
of clinical syndromes ranging from severe infantile encephalomyo-
pathy, hepatic failure and epilepsy, to late-onset ataxia, peripheral
neuropathy and myopathy, or isolated progressive external ophthal-
moplegia. However, visual failure is rare in this group of patients.
A recent unexpected addition to this list of genes linked to
nuclear mitochondrial disorders was OPA1, the major causative
gene in  60% of families with autosomal dominant optic atrophy
(DOA, OMIM 605290) (Alexander et al.,2 0 0 0 ;D e l e t t r eet al.,
2000; Yu-Wai-Man et al.,2 0 0 9 a). OPA1 consists of 30 exons span-
ning 100kb of genomic DNA on the long arm of chromosome 3
(3q28–q29), and the protein product is a 960 amino acid
polypeptide which co-localizes to the inner mitochondrial
membrane (Davies and Votruba, 2006). OPA1 contains a highly
conserved functional GTPase domain shared by members of
the dynamin superfamily of mechanoenzymes, and it regulates sev-
eral important cellular processes including the stability of the
mitochondrial network via its pro-fusion properties (Chan, 2007),
mitochondrial bioenergetic output through a postulated effect
on the assembly and stability of complex I and IV subunits
(Chevrollier et al., 2008; Zanna et al., 2008), and the sequestration
of pro-apoptotic cytochrome c molecules within the mitochondrial
cristae spaces (Cipolat et al., 2006; Frezza et al.,2 0 0 6 ) .
DOA is one of the most common inherited optic neuropathies
and it classically presents in early childhood with progressive visual
failure, with selective retinal ganglion cell loss as its deﬁning
pathological characteristic (Newman and Biousse, 2004;
Yu-Wai-Man et al., 2009a). However, even in the pre-molecular
era, patients with DOA and other clinical manifestations, most
commonly sensorineural deafness, ataxia, myopathy and progres-
sive external ophthalmoplegia, were recognized (Hoyt, 1980;
Meire et al., 1985). The signiﬁcance of these syndromal DOA
variants was recently highlighted by the identiﬁcation of
cytochrome c oxidase (COX)-deﬁcient muscle ﬁbres and multiple
mtDNA deletions in skeletal muscle biopsies from these patients,
implicating a previously unsuspected role of OPA1 in mtDNA
maintenance (Amati-Bonneau et al., 2008; Hudson et al., 2008;
Zeviani, 2008). Although intriguing from a mechanistic perspec-
tive, the broader clinical signiﬁcance of our observations was
unclear, given that only seven families had been identiﬁed.
We therefore conducted a systematic clinical and molecular
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DOA plus syndrome (DOA+) in OPA1 disease, describe the
phenotypic spectrum and the natural history of these additional
neuromuscular features, and deﬁne any genotype–phenotype
correlations.
Materials and methods
Patient cohorts
OPA1 positive families included in this study were identiﬁed from the
following groups.
(i) Our initial cohort was assembled as part of an ongoing
epidemiological study of inherited optic neuropathies in the
North of England. OPA1 screening was performed on pro-
bands with a clinical diagnosis of DOA where previous
investigations had excluded other compressive, inﬂammatory
and inﬁltrative causes for their bilateral optic atrophy.
Additional family members were examined both during the
initial diagnostic work up of the proband, and at the time of
active contact tracing following the identiﬁcation of a patho-
genic OPA1 mutation.
(ii) The relatively high prevalence of DOA+ phenotypes among
patients with OPA1 mutations in the North of England
prompted us to extend our original study to other diagnostic
and research centres with an interest in neuro-ophthalmologi-
cal disorders. DNA samples were analysed for patients with a
high suspicion of an underlying mitochondrial genetic disease
due to the multi-system pattern of their clinical presentations,
evidence of a mitochondrial biochemical defect, and/or the
presence of multiple mtDNA deletions. Visual failure was a
prominent feature of their phenotypes and when initial
screens for POLG1, POLG2, PEO1 and SLC25A4 were
found to be negative, OPA1 sequencing was performed.
In addition, we conducted a systematic review of the literature to
identify other DOA+ families with conﬁrmed OPA1 mutations. These
published data were included in our ﬁnal analysis to provide a
deﬁnitive description of the visual prognosis and genotype–phenotype
associations seen in DOA+.
Phenotypic evaluation
All patients harbouring pathogenic OPA1 mutations were comprehen-
sively assessed by a team of experienced ophthalmologists and
neurologists to deﬁne both the extent and the severity of their
ocular and neuromuscular deﬁcits. A complete orthoptic assessment
was performed to document any abnormalities of ocular motility, sup-
plemented by formal eye-movement recordings where appropriate.
Ancillary investigations including visual electrophysiology, peripheral
nerve conduction studies, electromyography, electroencephalography,
audiometry and neuroimaging were also performed as dictated by the
patient’s symptoms and the familial phenotype to conﬁrm possible
cases of non-penetrance.
Best corrected visual acuity was measured using the Snellen chart and
for the purpose of statistical analysis, Snellen ratios were converted to
LogMAR (logarithm of the minimum angle of resolution) decimal values.
A LogMAR value of 0 is equivalent to 6/6 Snellen vision and a value of
1.0 is equivalent to 6/60 Snellen vision, the largest optotype on standard
Snellen charts. Patients with visual acuities reduced to counting ﬁngers
were assigned a LogMAR value of 2.0, whilst those with only hand
movement perception were given a LogMAR value of 2.3
(Schulze-Bonsel et al., 2006; Lange et al., 2009).
Identiﬁcation of OPA1 mutations
The entire OPA1-coding region and ﬂanking exon–intron boundaries
were ampliﬁed by the polymerase chain reaction (PCR) and sequenced
with BigDye
TM terminator cycle chemistries on an appropriate genetic
analyser (Primers and cycling conditions are available on request).
Sequence chromatograms were compared with the Genbank OPA1
reference sequence (Accession number AB011139) and all genetic
variants were conﬁrmed by reverse sequencing. Novel OPA1
mutations not reported on the eOPA1 database (http://lbbma.univ-
angers.fr/eOPA1/) were screened in a panel of 150–300 age-matched
controls using (i) a multiplex primer extension assay and product ana-
lysis with matrix-associated laser desorption/ionization time of ﬂight
mass spectrometry (MALDI-TOF) (Sequenom, San Diego, CA); or
(ii) BigDye
TM sequencing of the relevant PCR-ampliﬁed OPA1 frag-
ments (Stewart et al., 2008).
Reverse-transcriptase PCR
Total RNA was extracted from blood samples with Trizol
TM reagent
(Invitrogen, Groningen, The Netherlands), and complementary DNA
was obtained using SuperScript
TM RNA polymerase and poly-T as
the primer (Invitrogen, Cergy Pontoise, France). PCR was performed
with the following primer pair: (i) forward 50-ACG CAA GAT CAT CTG
CCA CGG-30; and (ii) reverse 50-CCT GCT TGG ACT GGC TAC A-30,
to amplify a 597bp fragment overlapping OPA1 exons 9–14
(Amati-Bonneau et al., 2004). The generated products were analysed
on a 1% agarose gel and sequenced with BigDye
TM terminator cycle
chemistries.
Mitochondrial histochemistry
Skeletal muscle biopsies collected from 34 OPA1 mutation carriers
were snap frozen in melting liquid isopentane (–150 C) and then
stored at –80 C. The blocks were serially sectioned on a cryostat
before being stained for COX, succinate dehydrogenase (SDH) and
sequential COX–SDH activities, using standard histochemical protocols
(Johnson and Barron, 1996). The proportion of muscle ﬁbres exhibiting
a mitochondrial oxidative phosphorylation defect can be accurately
quantiﬁed, as normal COX-positive ﬁbres stain brown; whereas
COX-negative ﬁbres are highlighted blue as a result of impaired
complex IV activity. The histochemical ﬁndings in our DOA+ cohort
were compared with an age-matched control group of 20 skeletal
muscle biopsies from healthy subjects (mean age=51.1 years,
SD=10.7 years, P=0.4334) (Brierley et al., 1996).
Mitochondrial DNA deletion and
depletion assays
Multiple mtDNA deletions in homogenate skeletal muscle DNA were
identiﬁed by Southern blot and/or long-range PCR (Amati-Bonneau
et al., 2008; Hudson et al., 2008). mtDNA copy number was deter-
mined using a well-established iQ SYBR Green protocol on the
MyiQ
TM real-time PCR detection system (Biorad, USA), with MTND1
as the mtDNA reference gene and GAPDH as the nuclear DNA
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optimized and conﬁrmed to be linear over an appropriate concentra-
tion range by the standard curve method, and all measurements were
done in triplicate. The relative mtDNA copy number was derived using
the 2(2
–Ct) equation, where Ct was the difference in threshold cycle
value (Ct) between MTND1 and GAPDH, and accounting for two
copies of GAPDH per cell nucleus. mtDNA copy number in skeletal
muscle homogenate samples was also determined for a group of
age-matched healthy controls (mean age=43.1 years, SD=20.1
years, n=20, P=0.1300), and paediatric patients with known
mtDNA depletion syndromes (mean age=3.3 years, SD=2.7 years,
n=6, P50.0001).
Statistical analysis
Statistical analysis was performed using GraphPad
TM v.4 statistical
software (San Diego, CA). Fisher’s exact test and an independent
sample t-test were used for group comparisons, as required.
Prevalence ﬁgures were derived from the mid-2008 census data for
the North of England, and 95% CIs were calculated using Poisson
distribution variables for small numbers (Bland, 2000).
Results
OPA1 cohorts
The epidemiological study identiﬁed OPA1 mutations in 14 genet-
ically distinct OPA1 families, and a total of 64 affected family
members were living in the North of England. Their mean age
was 39.5 years (SD=17.8 years, range 6.0–78.0 years), with a
male to female ratio of 1.06:1, and DOA+ clinical features were
present in 11 out of 64 patients (17.2%) from 6 out of
14 (42.9%) families. In collaboration with other clinical centres,
49 additional DOA+ patients from 21 families harbouring OPA1
mutations were also found: British, n=8; French, n=5; Italian,
n=3; German, n=2; Norwegian, n=1; Austrian, n=1; and
Brazilian, n=1 (mean age=44.9 years, SD=18.4 years).
A systematic review of the literature revealed 18 published
OPA1 positive families segregating a DOA+ phenotype and clinical
information was available for 44 affected individuals (mean
age=43.5 years, SD=17.0 years, Table 1).
OPA1 mutations in DOA+
A total of 33 different OPA1 mutations were identiﬁed in these
45 independent DOA+ families: missense (n=18, 54.5%), non-
sense (n=2, 6.1%), splice site (n=8, 24.2%), and deletion (n=5,
15.2%) (Table 1, Fig. 1). A majority of these were located in the
GTPase regions (n=19, 57.6%), with a small cluster in the dyna-
min domain (n=4, 12.1%). We compared our ﬁndings to the
eOPA1 database (http://lbbma.univ-angers.fr/lbbma.php?id=9),
which currently lists 205 different OPA1 mutations, all of which
have been reported in patients with non-syndromal pure DOA.
There was a higher risk of developing a DOA+ phenotype with
missense mutations (OR=3.06, 95% CI=1.44-6.49, P=0.0027),
and mutations located in the GTPase region (OR=2.29, 95%
CI=1.08–4.82, P=0.0271) (Table 2). The risk of this occurring
was signiﬁcantly lower with mutations within the dynamin gene
domain (OR=0.28, 95% CI=0.10–0.84. P=0.0159) (Table 2).
We identiﬁed 9 novel OPA1 variants which were not found
in 150–300 age- and ethnically-matched control subjects:
(i) c.344C4T (p.A115V) in exon 2; (ii) c.768C4G (p.S256R) in
exon 5b; (iii) c.728T4A (p.L243X) in exon 7; (iv) c.854A4G
(p.Q285R) in exon 8; (v) c.1071A4G (p.A358A) in exon 11;
(vi) c.1327G4A (p.A443T) in exon 14; (vii) c.1462G4A
(p.G488R) in exon 15; (viii) c.1484C4T (p.A495V) in exon 15;
and (ix) c.1642G4A (p.V548I) in exon 17 (Supplementary Fig. 1).
With complementary DNA analysis, in-frame skipping of exon 12,
with the loss of 24 amino acids (p.T381-N404del), was
demonstrated for the c.1071A4G (p.A358A) synonymous substi-
tution. In two German siblings (DE-1), both the c.635_636del
(amino acid) deletion (p.K212fsX4) in exon 6 and the
c.1642G4A (p.V548I) missense mutation in exon 17 were present.
In the absence of additional clinical information and DNA samples
from other family members, it was not possible to determine
whether these variants were present on the same allele or were
compound heterozygous. A 60-year-old Norwegian proband
(NO-1) was compound heterozygous for the c.768C4G
(p.S256R) missense mutation in exon 5b and the c.854A4G
(p.Q285R) missense mutation in exon 8 (Table 1), and these two
variants were also identiﬁed in his 64-year-old, similarly affected,
sister. Both their parents, who are no longer alive, were apparently
healthy, and the proband’s two daughters, who are not visually
symptomatic, only harboured the c.768C4G substitution in exon
5b. Haplotype analysis conﬁrmed that the proband and his affected
sister were compound heterozygous for the c.768C4G (p.S256R)
and the c.854A4G (p.Q285R) mutations.
Major clinical features
Optic nerve dysfunction was present in 89/104 (85.6%) patients
with DOA+ features in our cohort (Table 3). In two, large,
three-generational families with autosomal dominant progressive
external ophthalmoplegia (IT-1 and IT-3), the penetrance of visual
failure was low (2/13, 15.4%), and if these are excluded, only
four of the remaining 91 cases (4.4%) were visually asymptomatic
with normal optic nerve parameters. Visual acuity data were avail-
able for 66 patients and they were compared with 42 patients
from the same families, but with only isolated optic
nerve involvement. The mean age of onset of visual loss was
8.2 years (SD=0.9 years) for the pure DOA group, and
7.7 years (SD=0.9 years) for the DOA+ group. This difference
was not statistically signiﬁcant (P=0.7255) and the majority of
individuals in both groups ( 95%) were symptomatic by the
age of 15 years (Fig. 2A). At the time of their last ophthalmolo-
gical assessment, the mean visual acuity was 0.87 LogMAR (6/44
Snellen) for patients with pure DOA, and 1.07 LogMAR (6/70
Snellen) for those with DOA+ phenotypes, this difference being
statistically signiﬁcant (P=0.0170) (Fig. 2B).
The second most common feature documented in DOA+
patients was deafness (65/104, 62.5%) which invariably followed
the onset of visual failure with a peak age of onset in the second
and third decades of life (Table 3). Pure-tone threshold audiome-
try was performed in 58 out of 65 cases and conﬁrmed
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Pedigree Age
(years)
Sex FHx Clinical features OPA1 mutations
Optic
atrophy
Deafness Ataxia Myopathy Neuropathy PEO Others Complementary
DNA
Amino acid
change
Domain
UK-1 54 M + + + c.1212+3a4t– –
UK-2 36 F + + + + Migraine c.870+5g4a– –
UK-2 55 F + + + + Migraine c.870+5g4a– –
UK-3 59 M + + + HSP Migraine c.876–878del(TGT) p.V294fsX667 –
UK-3 75
a M + + HSP c.876–878del(TGT) p.V294fsX667 –
UK-4 44 M + + + c.1198C4T p.P400S GTPase
UK-5 48 F + + + HSP c.889C4T p.Q297X –
UK-5 21 M + + HSP c.889C4T p.Q297X –
UK-6 58 F + + + MS c.2613+1g4a– –
UK-7 46 F + + c.2708_2711del(TTAG) p.V903fsX3 –
UK-8 44 F + + + + Diabetes c.32+1g4a– –
UK-8 53 M + + + Diabetes c.32+1g4a– –
UK-9 15 M + + + + c.1212+1G4A– –
UK-10 42 F + + c.1202G4A p.G401D GTPase
UK-11 70
a F + + + + + + c.1635C4G p.S545R Dynamin
UK-11 64 F + + + + + + + Diabetes c.1635C4G p.S545R Dynamin
UK-11 42 M + + + + c.1635C4G p.S545R Dynamin
UK-11 38 F + + + + + + + Migraine c.1635C4G p.S545R Dynamin
UK-11 30 M + + + + + + c.1635C4G p.S545R Dynamin
UK-12 43 M + + + + + + c.1294A4G p.I432V GTPase
UK-12 44 F + + + + + + c.1294A4G p.I432V GTPase
UK-12 69 F + + c.1294A4G p.I432V GTPase
UK-13 43 M + + + + c.1334G4A p.R445H GTPase
UK-14 44 F + + + + + c.1334G4A p.R445H GTPase
UK-14 42 F + + + + + c.1334G4A p.R445H GTPase
UK-14 73 M + + + + + c.1334G4A p.R445H GTPase
AU-1 35 F + + + + + + c.1635C4G p.S545R Dynamin
AU-1 34 F + + + + + + c.1635C4G p.S545R Dynamin
AU-1 61 F + + + + c.1635C4G p.S545R Dynamin
BE-1 72 F + + + + c.1334G4A p.R445H GTPase
BE-1 59 F + + + + c.1334G4A p.R445H GTPase
BE-1 29 F + + + + c.1334G4A p.R445H GTPase
BE-1 25 F + + + + c.1334G4A p.R445H GTPase
BR-1 9 M + + + CAPOS c.1327G4A p.A443T GTPase
CN-1 46 F + + + c.1334G4A p.R445H GTPase
CN-1 22 F + + + c.1334G4A p.R445H GTPase
CN-2 34 F + + + c.1202G4A p.G401D GTPase
CN-2 36 M + + + c.1202G4A p.G401D GTPase
CN-2 33 M + + + c.1202G4A p.G401D GTPase
CN-2 29 F + + + c.1202G4A p.G401D GTPase
CN-3 61 F + + + c.2848_2849del(GA) p.D950fsX4 –
CN-3 55 M + + + c.2848_2849del(GA) p.D950fsX4 –
CN-3 37 M + + + c.2848_2849del(GA) p.D950fsX4 –
CN-3 24 M + + + c.2848_2849del(GA) p.D950fsX4 –
DE-1 14 F + + + c.635_636del(AA) p.K212fsX4 –
c.1642G4A p.V548I Dynamin
DE-1 13 F + + + c.635_636del(AA) p.K212fsX4 –
c.1642G4A p.V548I Dynamin
DE-2 11 M + + + c.1313A4T p.D438V GTPase
ES-1 57 F + + + + + + Dementia c.1334G4A p.R445H GTPase
ES-1 30 F + + + c.1334G4A p.R445H GTPase
FI-1 F + + + c.970_978del(9) p.R324_P326del –
FR-1 30 M + + + + + + c.1635C4G p.S545R Dynamin
FR-2 35 F + + + + c.1334G4A p.R445H GTPase
FR-3 14 M
b + + c.1334G4A p.R445H GTPase
FR-4 39 M + + + + + c.728T4A p.L243X –
FR-5 53 M + Epilepsy c.1071A4G p.A358A
c –
FR-6 12 F + + c.1334G4A p.R445H GTPase
(continued)
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Pedigree Age
(years)
Sex FHx Clinical features OPA1 mutations
Optic
atrophy
Deafness Ataxia Myopathy Neuropathy PEO Others Complementary
DNA
Amino acid
change
Domain
FR-7 20 M + + c.1334G4A p.R445H GTPase
FR-8 38 F + + + c.1334G4A p.R445H GTPase
FR-9 43 M + + + + + + + c.1635C4G p.S545R Dynamin
FR-10 67 M + + + + + + c.1069G4A p.A357T GTPase
FR-11 44 M + MS c.1937C4T p.S646L Dynamin
IT-1 64 F + + + + + c.1462G4A p.G488R GTPase
IT-1 64
a M + + + + + + Dementia c.1462A4G p.G488R GTPase
IT-1 36
a M + + + Migraine, epilepsy c.1462A4G p.G488R GTPase
IT-1 72 F + + + + + + c.1462A4G p.G488R GTPase
IT-1 69 M + + + + + + Migraine c.1462A4G p.G488R GTPase
IT-1 46 F + + + c.1462A4G p.G488R GTPase
IT-1 44 M + + + c.1462A4G p.G488R GTPase
IT-1 53 M + + + c.1462A4G p.G488R GTPase
IT-2 12 F + + + c.344C4T p.A115V Basic
IT-3 69 M + + + + + c.1484C4T p.A495V GTPase
IT-3 60 M + + + c.1484C4T p.A495V GTPase
IT-3 62 M + + + c.1484C4T p.A495V GTPase
IT-3 39 F + + + c.1484C4T p.A495V GTPase
IT-3 68 M + + + + c.1484C4T p.A495V GTPase
IT-4 38 M + + + + + + + c.1316G4T p.G439V GTPase
IT-4 6 F + + + c.1316G4T p.G439V GTPase
IT-5 59 M + + + c.2729T4A p.V910D GE
IT-5 53 M + + + c.2729T4A p.V910D GE
IT-6 47 F + + + c1410_1443+4del(38) p.D470fsX13 –
IT-6 46 F + + + c1410_1443+4del(38) p.D470fsX13 –
IT-7 42 M + + + + c.1745A4G p.Y582C Dynamin
NO-1 60 M + + + + + Spasticity c.768C4G p.S256R CC
c.854A4G p.Q285R GTPase
NO-1 64 F + + + + + Spasticity c.768C4G p.S256R CC
c.854A4G p.Q285R GTPase
NO-1 43 F + c.768C4G p.S256R CC
NO-1 35 F + c.768C4G p.S256R CC
US-1 71 M + + + + c.1334G4A p.R445H GTPase
US-1 68 F + + + + c.1334G4A p.R445H GTPase
US-1 64 M + + + + c.1334G4A p.R445H GTPase
US-1 56 M + + + + c.1334G4A p.R445H GTPase
US-1 77 F + + + + c.1334G4A p.R445H GTPase
US-1 64 F + + + + c.1334G4A p.R445H GTPase
US-1 49 F + + + c.1334G4A p.R445H GTPase
US-1 45 F + + + + c.1334G4A p.R445H GTPase
US-1 38 M + + + + c.1334G4A p.R445H GTPase
US-1 42 M + + + + c.1334G4A p.R445H GTPase
US-1 43 F + + + c.1334G4A p.R445H GTPase
US-1 51 F + + + + c.1334G4A p.R445H GTPase
US-1 26 F + + + c.1334G4A p.R445H GTPase
US-1 19 F + + + c.1334G4A p.R445H GTPase
US-2 48 F + + + c113_130del(18) p.R38_S43del –
AU=Austria; BE=Belgium; BR=Brazil; CN=China; DE=Germany; ES=Spain; FI=Finland; FR=France; IT=Italy; NO=Norway; UK=United Kingdom; US=USA;
AA=amino acid; FHx=family history; HSP=hereditary spastic paraplegia; MS=multiple sclerosis-like illness; CAPOS=cerebellar ataxia, areﬂexia, pes cavus, optic atrophy
and sensorineural hearing loss; CC=coiled-coil domain; GE=GTPase effector domain; PEO=progressive external ophthalmoplegia.
aAge of death.
bDe novo OPA1 mutation.
cIn-frame skipping of exon 12 (p.T381-N404del).
BE-1: (Meire et al., 1985; Payne et al., 2004); CN-1: (Li et al., 2005); CN-2: (Ke et al., 2006); CN-3: (Chen et al., 2007); ES-1: (Amati-Bonneau et al., 2005); FI-1: (Puomila
et al., 2005); FR-6, FR-7, FR-8:(Amati-Bonneau et al., 2005); FR-9, FR-10: (Amati-Bonneau et al., 2008); IT-4: (Amati-Bonneau et al., 2008; Liguori et al., 2008); IT-5:
(Amati-Bonneau et al., 2008); IT-6: (Spinazzi et al., 2008); IT-7: (Ferraris et al., 2008); UK-11: (Hudson et al., 2008); UK-12, UK-13, UK-14: (Stewart et al., 2008); US-1:
(Payne et al., 2004); US-2: (Milone et al., 2009).
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fered from hearing loss, 39 out of 65 (60.0%) also developed
signiﬁcant neuromuscular deﬁcits in later life, and these were a
combination of progressive external ophthalmoplegia (48/104,
46.2%), proximal myopathy (37/104, 35.6%), ataxia (31/104,
29.8%), and axonal sensory and/or motor neuropathy (31/104,
29.8%). These additional features became manifest from the third
decade of life onwards, with on average a slightly later age of
onset for progressive external ophthalmoplegia. Subclinical nerve
conduction abnormalities were detected in two of the 31 individ-
uals who were investigated further because of their strong familial
phenotype, and neurophysiological studies were normal in nine
patients with symptoms suggestive of a possible neuropathic
component.
Novel presentations
Spastic paraplegia
In two families with clinically presumed autosomal dominant
hereditary spastic paraplegia (HSP), pathogenic OPA1 mutations
were identiﬁed segregating with both optic atrophy and spastic
paraparesis: (i) a 3-bp in-frame deletion c.876-878del(TGT) in
exon 9 (p.V294fsX667) (UK-3); and (ii) a nonsense GTPase
mutation c.889C4T in exon 9 (p.Q297X) (UK-5), which are pre-
dicted to result in premature termination codons. Prior to OPA1
screening, the probands were extensively investigated to establish
Figure 1 Diagrammatic representation of the OPA1 gene with the location of mutations resulting in DOA+ syndromes. The mutation
type is indicated by (i) red stars (missense); (ii) grey squares (nonsense); (iii) blue circles (splice site); and (iv) green triangles (deletion).
CC=coiled-coil domain; GE=GTPase effector domain; UTR=untranslated region.
Table 2 Odd ratios for developing a DOA+ phenotype based upon OPA1 mutation type and domain
OPA1
mutations
eOPA1
a This study
b OR 95% CI P-value
Type (n) Missense 55 18 3.06 1.44–6.49 0.0027 
Nonsense 34 2 0.31 0.07–1.34 0.0975
Splice 55 8 0.81 0.35–1.92 0.6378
Deletion 51 5 0.50 0.18–1.38 0.1745
Domain (n) GTPase 76 19 2.29 1.08–4.82 0.0271 
Dynamin 67 4 0.28 0.10–0.84 0.0159 
Others 61 10 1.02 0.46–2.27 0.9628
CI=conﬁdence interval, OR=odds ratio.
aeOPA1 online database (http://lbbma.univ-angers.fr/lbbma.php?id=9).
bMeta-analysis of 33 OPA1 mutations which includes nine previously published OPA1 mutations. *=Signiﬁcant P-value.
Table 3 Major clinical features observed in DOA+ patients
Clinical features
a n % 95% CI
Lower Upper
Optic atrophy 89/104 85.6 77.5 91.2
Deafness 65/104 62.5 52.9 71.2
Ataxia 31/104 29.8 21.8 39.2
Neuropathy 31/104 29.8 21.8 39.2
Myopathy 37/104 35.6 27.0 45.2
Progressive external
ophthalmoplegia
48/104 46.2 36.9 55.7
CI=conﬁdence interval.
aMeta-analysis of 104 OPA1 mutation carriers from 45 DOA+ families, which
includes previously published data on 44 individuals from 18 DOA+ families.
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negative: cerebrospinal ﬂuid (CSF) studies, metabolic screen,
brain and spinal cord MRI, and SPG4 genetic testing. In family
UK-3, the proband was a 59-year-old man who ﬁrst presented to
a neurologist when he was 46-years-old with marked lower limb
spasticity, in addition to complicated migraine and poor vision
(counting ﬁngers, both eyes), which was noted at the time of
preschool vision screening. His spastic paraplegia has gradually
worsened over the years and he had more recently developed
an axonal sensorimotor neuropathy. His maternal uncle who
died at the age of 75-years-old was similarly affected but both
of the proband’s two sons have isolated optic atrophy and no
subjective problems with their legs. In family UK-5, the proband
was a 48-year-old woman with progressive gait and balance
difﬁculties going back to her mid-thirties and severe visual
failure from early childhood (counting ﬁngers, both eyes). Her
neuro-ophthalmological investigations conﬁrmed bilateral total
optic atrophy, lower limb spasticity with spontaneous ankle
clonus, and a predominantly axonal sensory neuropathy on
nerve conductions studies. Her 21-year-old son was a mutational
carrier and although visually asymptomatic (6/6, both eyes), he
had subtle temporal disc pallor and lower limb spasticity which had
previously been ascribed to cerebral palsy. His 26-year-old sister
also had evidence of mild optic nerve involvement (6/9, both
eyes) but her neurological examination was otherwise normal.
Multiple sclerosis-like illness
A 58-year-old woman was referred by her optometrist following a
routine eye test with suspected bilateral optic atrophy (UK-6). She
had no visual complaints (6/9, both eyes) but on examination her
colour vision was severely reduced, with bilateral small
caeco-central scotomas on Goldmann ﬁeld perimetry. She had
mild gait ataxia and a comprehensive neurological assessment
revealed periventricular white matter lesions on MRI, and
unmatched oligoclonal bands in her CSF, both supportive of an
underlying demyelinating process clinically indistinguishable from
multiple sclerosis (Fig. 3). Two of her brothers, aged 61 and 63
years old, had previously been investigated for poor vision and a
label of Leber hereditary optic neuropathy was given, even though
a screen for the three primary Leber hereditary optic neuropathy
mtDNA point mutations (m.3460G4A, m.11778G4A and
m.14484T4C) was negative. The family history was also consis-
tent with an autosomal dominant pattern of inheritance and this
prompted OPA1 genetic screening, which uncovered a
c.2613+1g4a splice-site mutation within intron 25 segregating
with affected disease status in both the proband and her two
brothers.
Additional clinical features
Late-onset non-insulin dependent diabetes developed in 3 of the
83 (3.6%) DOA+ patients and this was associated with deafness
in one case. Recurrent migrainous-type headaches were also
reported by 4 of the 83 (4.8%) patients in our DOA+ cohort:
(i) a 36-year-old woman with the c.870+5g4a mutation (UK-2);
(ii) her 54-year-old sister who also carried the c.870+5g4a
mutation; (iii) a 59-year-old man with the c.876_878del(TGT)
deletion (UK-3); and (iv) a 38-year-old woman with the
c.1635C4G mutation (UK-11). The onset was in their mid to
late teens, three of the four (75.0%) described a prodromal
phase characterized by positive visual phenomena and photopho-
bia, and all four of them experienced a stereotypical pattern char-
acterized by severe fronto-temporal headaches associated with
nausea and vomiting. Additional complicated features included
Figure 2 (A) Cumulative distribution curve of age on onset of visual failure in pure DOA and DOA+, and (B) comparison of mean
LogMAR visual acuity between patients with pure DOA and DOA+ features (P=0.0170). The whiskers represent the minimum and
maximum LogMAR values, the ends of the boxes are the upper and lower quartiles, the vertical length of the boxes indicate the
interquartile range, and the line within the boxes represent the median LogMAR values for each group.
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state after the headache had subsided.
Neuroimaging and metabolic ﬁndings
Neuroimaging abnormalities were identiﬁed in 12 of the
40 (30.0%) DOA+ patients: (i) bilateral basal ganglia calciﬁcations
(n=2, 5.0%); (ii) periventricular multiple sclerosis-like lesions
(n=2, 5.0%); (iii) non-speciﬁc white matter lesions (n=4,
10.0%); and (iv) varying degrees of cortical and cerebellar atrophy
(n=5, 12.5%). Brain magnetic resonance spectroscopy was per-
formed on a 43-year-old man with a complex DOA+ phenotype
due to a c.1635C4G mutation in exon 17 (FR-9). His MRI scan
showed mild cortical and cerebellar atrophy, but both n-acetyl-
aspartate and lactate peaks were not altered on his magnetic
resonance spectroscopy spectra. CSF analysis performed on
29 DOA+ patients was unremarkable, except for the two patients
with periventricular white matter lesions (UK-6 and FR-11), who
both had unmatched oligoclonal bands. There was no evidence of
marked metabolic derangement in our patient cohort. Plasma lac-
tate levels were elevated in only ﬁve patients, and no abnormal
organic acids proﬁle was reported in the subgroup of patients with
ataxia and spastic paraplegia.
Histochemical studies
Dual COX–SDH staining was performed on skeletal muscle biop-
sies from 10 patients with pure DOA (mean age=49.3 years,
SD=9.6 years, range=39.0-65.0 years) and 24 patients with
DOA+ phenotypes (mean age=50.6 years, SD=11.0 years,
range=24.0-69.0 years), and there was no signiﬁcant age differ-
ence between these two groups (P=0.7354). Published muscle
biopsy data from an additional four patients with features of
DOA+ were also included in the meta-analysis (Ferraris et al.,
2008; Spinazzi et al., 2008; Milone et al., 2009). The frequency
of COX-deﬁcient muscle ﬁbres in the pure DOA group
(mean=1.30%, SD=1.20%, range=0–3.00%) was signiﬁcantly
lower than in the DOA+ group (mean=5.41%, SD=5.90%,
range=0–21.18%, P=0.0226, Fig. 4A). However, COX-deﬁcient
ﬁbres were signiﬁcantly more frequent in both pure DOA
(P50.0001) and DOA+ patients (P50.0001), compared to con-
trols (mean=0.03%, SD=0.07%, range=0–0.30%, Fig. 4B).
Mitochondrial DNA analysis
There was clear evidence of multiple mtDNA deletions in
skeletal muscle in the majority of patients with both pure DOA
Figure 3 Molecular investigations and MRI neuroimaging of a 58-year-old female presenting with a multiple sclerosis-like illness and
harbouring a c.2613+1g4a splice-site mutation within intron 25 of the OPA1 gene (UK-6). (A) Family tree of the affected proband (II-3).
DNA samples were obtained from her 62-year-old (II-1) and 59-year-old (II-2) brothers, who both had a pure DOA phenotype, and OPA1
sequencing conﬁrmed the presence of the same heterozygous c.2613+1g4a variant. The asterisk indicates family members where DNA
samples were available for molecular analysis. (B) A 16kb long-range PCR assay was performed on homogenate DNA extracted from the
patient’s skeletal muscle biopsy, and multiple deletion bands were identiﬁed. Lane a: 1kb DNA ladder with the adjacent numbers
indicating the size of the band; lane b: patient; lane c: wild-type control. (C) Axial T2-weighted ﬂuid attenuated inversion recovery and
(D) sagittal T2-weighted turbo spin echo slices showing cortical atrophy and characteristic white matter lesions in the periventricular areas
and more peripherally near to grey matter.
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with no signiﬁcant difference between these 2 groups
(
2=0.1810, P=0.6706, Table 4). For the four patients with
DOA+ features but no multiple mtDNA deletions on long-range
PCR, COX-negative ﬁbres were also not detected in their muscle
biopsies (mean age=45.5 years, SD=7.9 years, range=35.0–54.0
years). This speciﬁc subgroup harboured two different splice-site
mutations: c.1212+3a4t (UK-1) and c.870+5g4a (UK-2), and a
Figure 5 Clinical, histochemical and molecular features observed in a 59-year-old female with isolated optic nerve involvement due to
an exon 27c.2713C4T (p.R905X) OPA1 missense mutation. (A) Right, and (B) left optic discs displaying generalized pallor of the
neuro-retinal rim and pathological excavation. (C) Dual COX-SDH histochemistry performed on 20mm thick cryostat sections showing the
presence of COX-deﬁcient muscle ﬁbres (33/1100, 3.00%). (D) Long-range PCR of the patient’s homogenate skeletal muscle DNA
revealing multiple deletion bands in addition to the wild-type 16-kb fragment. Lane a: 1-kb DNA ladder with the adjacent numbers
indicating the size of the band; lane b: patient; lane c: wild-type control.
Figure 4 Mean level of COX-deﬁciency in skeletal muscle biopsies: (A) pure DOA versus DOA+ phenotypes (P=0.0226) and (B) pure
DOA versus age-matched controls (P50.0001). The error bars represent the standard error of the mean.
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(Spinazzi et al. 2008). Repeat muscle biopsies were available for
two patients. The ﬁrst was a 36-year-old woman with proximal
myopathy, peripheral neuropathy, complicated migraine and the
c.870+5g4a splice-site mutation (UK-2). Muscle biopsies were
taken when she was 25- and 35-years-old, and both showed
no evidence of COX-deﬁciency or multiple mtDNA deletions
on long-range PCR. In contrast, her 55-year-old sister, who had
a remarkably similar clinical picture, had deﬁnite evidence of multi-
ple mtDNA deletions on long-range PCR with normal COX-SDH
staining in a muscle biopsy taken at the age of 54 years. The
second was a 59-year-old man with an HSP-like phenotype, com-
plicated migraine and the c.876_878del(TGT) deletion (UK-3). His
most recent muscle biopsy taken when he was 58-years-old
revealed 2.07% (10/482) COX-deﬁcient ﬁbres and a laddering
pattern on long range PCR indicating multiple deleted mtDNA
species. Histochemical and molecular studies on a skeletal muscle
specimen taken 13 years earlier, when his lower limb spasticity
was much less severe, were entirely normal. There was no evi-
dence of mtDNA depletion in skeletal muscle homogenate DNA
from OPA1 positive patients (mean mtDNA copy number=5144,
SD=2843, n=24) when compared to age-matched healthy con-
trols (mean mtDNA copy number=4669, SD=2640, n=20,
P=0.5719; Fig. 6).
Discussion
By studying 45 DOA+ families from different geographical back-
grounds, we have shown that additional neuromuscular features
frequently develop as the disease progresses, with an adverse
impact on the pre-existing visual morbidity. A meta-analysis of
104 patients with DOA+ phenotypes, including 44 previously
reported cases in the literature, conﬁrmed that sensorineural deaf-
ness is the most frequently observed extra-ocular feature, present
in nearly two-thirds of all patients, over half of whom eventually
developed more severe neuromuscular symptoms. Progressive
external ophthalmoplegia and a predominantly axonal sensory
neuropathy were the next most common clinical manifestations,
followed by ataxia and myopathy. Although there is a degree
of overlap, a chronological pattern is emerging with visual failure
occurring within the ﬁrst decade of life, followed by deafness from
late childhood to early adulthood, and then a combination of
ataxia, myopathy, peripheral neuropathy and progressive external
ophthalmoplegia from the third decade of life onwards (Fig. 7).
Excluding singleton cases and subjects younger than 25-years-old,
it is also remarkable that in about a third of all pedigrees (11/32,
34.4%), family members were found to manifest both pure DOA
and DOA+ phenotypes despite carrying the same OPA1 mutation,
and presumably having shared common environmental inﬂuences,
especially in the ﬁrst two decades of life in parent-offspring cases.
Optic nerve sparing
OPA1 mutations were identiﬁed in two large Italian pedigrees
(IT-1 and IT-3) segregating autosomal dominant progressive exter-
nal ophthalmoplegia, and remarkably, only a minority of family
members were visually symptomatic with evidence of optic
atrophy (2/13, 15.4%). In sharp contrast, almost all of the
remaining DOA+ cases had evidence of optic nerve dysfunction
(87/91, 95.6%), and the published penetrance ﬁgures are gener-
ally 480% in well characterized, multi-generational families with
pure DOA (Yu-Wai-Man et al., 2009a). The observation in these
two Italian families has important diagnostic implications, and it
will be important to screen a larger cohort of autosomal dominant
progressive external ophthalmoplegia pedigrees without prominent
visual symptoms, to determine the true prevalence of OPA1 muta-
tions in this speciﬁc disease subgroup. Furthermore, it is intriguing
that OPA1 mutational carriers can be non-penetrant for optic
nerve failure, but yet manifest other deﬁcits including deafness,
myopathy and peripheral neuropathy, besides progressive external
ophthalmoplegia. This is critically important, because it means that
clinicians should consider OPA1 screening in patients with unex-
plained neurological features, especially if molecular investigations
Figure 6 Comparison of mtDNA copy number in homogenate
skeletal muscle DNA from patients with OPA1 mutations
(mean=5144, SD=2843, n=24) with age-matched healthy
controls (mean=4669, SD=2640, n=20, P=0.5719), and
patients with mtDNA depletion syndromes (mean=524,
SD=345, n=6,P=0.0005). The error bars represent the
standard error of the mean.
Table 4 Summary of OPA1 mutations and molecular
proﬁle identiﬁed in patients with DOA+ phenotypes
OPA1 mutations
Missense Nonsense Splice
site
Deletion
DOA+patients n 80 3 8 13
COX-deﬁciency
a   1– 3 2
+ 17 1 2 2
MtDNA deletions
a   –– 2 2
+ 18 1 3 2
aFor DOA+ patients where muscle biopsies were available for histochemical and
molecular analysis (n=28).
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(Stewart et al., 2008).
Expanding DOA+ phenotype
We indentiﬁed several unexpected phenotypes in patients with
OPA1 mutations, including spastic paraparesis and a multiple
sclerosis-like illness, and these are unlikely to be chance associa-
tions. In the two probands presenting with progressive lower limb
spasticity (UK-3 and UK-5), no underlying metabolic, inﬂamma-
tory or compressive causes were found despite extensive investi-
gations over several years. Isolated spastic paraparesis is unusual in
adults with mitochondrial disease (Corona et al., 2002), and the
degeneration of corticospinal tract axons seen in these
two families is particularly revealing. Further studies into the
mechanisms involved could provide important insights into
the pathophysiological mechanisms at work in hereditary spastic
paraplegia, the obvious corollary being that the OPA1 mutation is
having a negative impact on neuronal survival by creating an
imbalance in mitochondrial network dynamic and axonal trafﬁck-
ing (Reid, 2003; Salinas et al., 2008). The presence of
COX-deﬁcient ﬁbres and multiple mtDNA deletions in skeletal
muscle biopsies is also very signiﬁcant and further supports a
link with mitochondrial dysfunction in a subgroup of patients
with hereditary spastic paraplegia (McDermott et al., 2003).
The unmatched CSF oligoclonal bands and abnormal white
matter lesions in the 58-year-old woman with a multiple
sclerosis-like illness (UK-6) are also unlikely to be co-incidental
ﬁndings. Based upon recent epidemiological data (Fox et al.,
2004), we estimate the chance ﬁnding of an OPA1 mutation in
a patient with multiple sclerosis in the UK at 1 in 41 million (95%
CI=25–73 million), and of note, this association has already been
reported in a 44-year-old man with gait ataxia and lower-limb
spasticity (FR-11), who had MRI and CSF changes consistent
with a demyelinating process, and a novel c.1937C4T (p.S646L)
missense mutation in the dynamin region the OPA1 gene (Verny
et al., 2008). These observations are reminiscent of the
well-established association between primary mtDNA Leber hered-
itary optic neuropathy mutations and a multiple sclerosis-like
illness (Harding’s disease) (Harding et al., 1992; Kovacs et al.,
2005), and it is therefore tempting to speculate a causal
link between OPA1 mutations, mitochondrial dysfunction,
oligodendrocyte survival and the complex autoimmune process
which underlies the pathophysiology of multiple sclerosis (Carelli
and Bellan, 2008; Mahad et al., 2009).
Nearly a third of all the DOA+ patients in our study had evi-
dence of an axonal neuropathy, an observation with important
parallels to a speciﬁc subtype of Charcot-Marie-Tooth (CMT)
disease or, hereditary motor and sensory neuropathy type VI
(HMSN VI, OMIM 601152). This variant is caused by mutations
in the MFN2 gene and it is characterized by early onset, severe
peripheral neuropathy in the ﬁrst decade of life, followed by sub-
acute, progressive optic atrophy in later childhood (Zuchner et al.,
2006). Mitofusin-2 is located within the mitochondrial outer mem-
brane and it shares a high degree of structural and functional
complementarity with Opa1, both being dynamin GTPase proteins
(Zuchner et al., 2006; Chan, 2007). Mitofusin-2 interacts closely
with Opa1 to promote fusion of the mitochondrial network, and it
could also play a distinct role in mitochondrial oxidative output by
regulating the expression of nuclear-encoded respiratory chain
subunits (Pich et al., 2005). It is also noteworthy that abnormal
nerve conduction studies were documented in two DOA+ patients
with no overt neuropathic features. As neurophysiological investi-
gations were performed mostly to conﬁrm a suspected peripheral
neuropathy, the true burden of subclinical disease remains to be
determined, not only in DOA+, but also among patients with pure
DOA.
The prevalence of non-insulin dependent diabetes in our DOA+
cohort (3.6%) was comparable to the latest UK national ﬁgures
(3.9%) (NHS Quality and Outcomes Framework, 2008), and
although severe, characteristic migrainous episodes were reported
by 4 out of 83 (4.8%) patients with DOA+, this could simply
reﬂect the background prevalence of migraine in the general pop-
ulation (11–15%), and not an OPA1-related effect per se
(Goadsby et al., 2002; Bigal et al., 2006).
Prevalence of DOA+
As a result of the different referral patterns in this study, the
prevalence of patients with DOA+ phenotypes is difﬁcult to ascer-
tain. However, a reasonable estimate can be derived from our
epidemiological data from the North of England, which has a
centralized National Health Service with well deﬁned catchment
areas (Man et al., 2003). Based upon our latest ﬁgures, 64 patients
Figure 7 Evolution of the major clinical features observed in DOA+ syndromes.
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and of those 11 out of 64 (17.2%) had DOA+ features, suggest-
ing that these syndromal manifestations are not uncommon and
probably affect up to one in six of all cases. Using the latest census
data for the North of England (Ofﬁce for National Statistics,
2008), we estimate the minimum prevalence of DOA+ at 0.36
per 100000 (95% CI=0.25–0.50 per 100000); about 1 in
250000 of the general population. This is comparable to other
well-recognized neurogenetic disorders with prominent ocular fea-
tures such as oculopharyngeal muscular dystrophy (Brais, 2009),
neuromyelitis optica (Devic disease) (Wingerchuk et al., 2007),
and diabetes insipidus and mellitus with optic atrophy and deaf-
ness (Wolfram syndrome 1) (Khanim et al., 2001).
Novel OPA1 mutations
We have identiﬁed an additional nine novel OPA1 mutations in
this study, adding to the list of 4200 pathogenic variants so far
catalogued on the eOPA1 database (Ferre et al., 2005, 2009).
Unusually, in two families, DE-1 and NO-1, affected family mem-
bers harboured two different OPA1 mutations. Only one other
case of compound heterozygosity has previously been described
in a female patient from a German family, and she carried two
presumed pathogenic substitutions in exon 8: c.808G4A
(p.E270K) and c.868C4T (p.R290W) (Pesch et al., 2001). The
patient’s visual loss was more severe compared with ﬁve other
affected family members who were all simple heterozygotes,
which led the authors to speculate that her greater visual impair-
ment was related to the presence of two pathogenic OPA1
variants. Unlike this previously published family who only exhib-
ited isolated optic atrophy, both DE-1 and NO-1 had
DOA+features, with the two Norwegian siblings having a partic-
ularly aggressive disease course characterized by ataxia, peripheral
neuropathy, corticospinal tract involvement and myopathy, in con-
trast to relatively mild sensorineural hearing loss for the two
German siblings. Although the number of cases is small,
it is tempting to invoke a combined mutational effect, with the
presence of two OPA1 mutations leading to greater disease
severity.
The Norwegian family, NO-1, is also unusual in carrying an
exon 5b missense mutation, c.768C4G (p.S256R), in the
coiled-coil domain of the Opa1 protein. Using in silico modelling,
the change of a serine to arginine at position 256 is predicted to
result in a marked reduction in the likelihood of coiled-coil forma-
tion in this region (Fig. 8), with a detrimental effect on the ability
of the Opa1 protein to form oligomers, which is critical for its
normal function. We previously reported another exon 5b
mutation, c.740G4A (p.R247H), in a 23-year-old male with
pure DOA and a unique clinical course characterized by sponta-
neous, progressive visual recovery (Cornille et al., 2008). This
amino acid substitution was also identiﬁed in the patient’s father
who was non-penetrant for optic atrophy. The c.740G4A
(p.R247H) mutation was predicted to disrupt the coiled-coil
forming potential, and in addition, ﬁbroblasts harvested from
both family members showed mitochondrial network abnormalities
and oxidative phosphorylation uncoupling, with a greater suscep-
tibility to undergo apoptosis (Cornille et al., 2008).
It is therefore interesting that only the c.768C4G (p.S256R)
variant was identiﬁed in the two, visually asymptomatic, 35- and
43-year-old daughters of the Norwegian proband. OPA1 mRNA
exists as eight isoforms as a result of alternate splicing of exons 4,
4b and 5b, and from an evolutionary perspective, exons 4b and
5b are only found in higher vertebrates with a putative role in
regulating cytochrome c release during apoptosis (Olichon et al.,
2007). The 37 amino acids encoded by exon 5b are identical in all
higher vertebrates and only two substitutions have so far been
reported, both non-synonymous. Although speculative, as exon
5b is only present in  40% of total OPA1 mRNA transcripts,
this could explain the relatively mild pathogenic nature of exon
5b variants on their own. Additional functional studies, for exam-
ple comparing ﬁbroblast cell lines from NO-1 family members, are
also warranted to further clarify whether there is a synergistic
action between the exon 5b and the exon 8 variants in compound
heterozygous individuals, contributing to disease severity.
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Figure 8 In silico prediction of coiled-coil regions within the
segment of 37 amino acids encoded by exon 5b: (A) wild-type,
and (B) p.S256R substitution. The modelling accuracy increases
with larger scanning windows (28421414), and probabilities
40.5 indicate a high likelihood of coiled-coil conformation. The
p.S256R substitution is predicted to reduce the coiled-coil
forming potential by  45%. (http://www.ch.embnet.org/soft
ware/COILS_form.html). Green line=window 14; Blue
line=window 21; Red line=window 28.
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In our original description of multiple mtDNA deletions in DOA+,
all the OPA1 mutations were missense substitutions and in 5/7
families, these clustered in the GTPase domain (Amati-Bonneau
et al., 2008; Hudson et al., 2008). A possible dominant negative
effect was therefore suggested with the mutant Opa1 protein
disrupting mitochondrial inner membrane function and/or the
delicate balance of the intra-mitochondrial nucleotide pool
required for efﬁcient mtDNA replication (Zeviani, 2008).
Although these remain to be proven experimentally, a gain of
function mechanism cannot explain the association of OPA1 dele-
tions and splice-site mutations with DOA+, both of which lead to
haploinsufﬁciency, and were identiﬁed in DOA+ families in this
study.
Histochemical and molecular studies performed on skeletal
muscle biopsies from patients with both pure DOA and DOA+
features have also provided some interesting insights into the pos-
sible disease mechanisms involved in retinal ganglion cell loss and
optic nerve degeneration. COX-deﬁciency is a useful surrogate
marker of the extent of mitochondrial dysfunction due to
mtDNA defects, and consistent with this, patients with DOA+
phenotypes had over four times higher levels of COX-negative
muscle ﬁbres compared to patients with pure DOA. The majority
of patients in both subgroups harboured multiple mtDNA dele-
tions, but in a few patients with DOA+ features, both
COX-deﬁciency and secondary mtDNA deletions were not
present, even when using long-range PCR, a highly sensitive
technique that preferentially ampliﬁes smaller mtDNA species
(Lightowlers et al., 1999). It is therefore possible that mtDNA
deletions contribute to the pathophysiology of DOA, but they
are not the sole mechanism responsible for triggering cellular dys-
function, especially optic nerve neurodegeneration. In keeping
with this hypothesis, we recently showed that secondary mtDNA
abnormalities were not present in retinal ganglion cells harvested
from a pure DOA mouse model, implying that retinal ganglion cell
loss must be the result of other deleterious consequences induced
by the OPA1 mutation (Yu-Wai-Man et al., 2009b). One impor-
tant caveat is that the molecular observations in this study relate
to skeletal muscle biopsies, which might not be a true reﬂection of
the changes operating within retinal ganglion cells, tissue-speciﬁc
mechanisms being well-recognized features of mitochondrial
disorders.
The Opa1 protein is involved in several inter-related biological
processes and further studies are needed to clarify whether speciﬁc
mutations operate predominantly via certain pathways (Davies and
Votruba, 2006; Yu-Wai-Man et al., 2009a). These are not how-
ever mutually exclusive, for example, increased levels of reactive
oxygen species secondary to disturbed oxidative phosphorylation
could potentiate the formation of mtDNA deletions (Krishnan
et al., 2008), and mitochondrial network fragmentation could
accelerate their clonal expansion, the compartmentalization of
the mtDNA pool effectively decreasing the copy number in
these discrete units, and reducing the time required for the deleted
mtDNA species to reach supra-threshold levels (Chinnery and
Samuels, 1999).
Genotype–phenotype correlations
Genetic counselling has always been a challenging issue in DOA
due to the marked intra- and inter-familial variability in visual
prognosis, and these difﬁculties have now been further com-
pounded by the heterogeneous individual manifestations of
DOA+ features. Although further studies are warranted, our
study has allowed us to deﬁne some broad genotype–phenotype
correlations for clinicians advising patients on the implications of
the OPA1 mutations segregating in their families: (i) mutations
causing optic atrophy in association with sensorineural deafness
are not limited to the c.1334G4A (p.R445H) variant but, as in
other reports, we found this mutation to be the most common,
being present in 11 out of 30 (36.7%) families in our study;
(ii) there is a 2–3-fold increased risk of developing DOA+ features
with missense mutations and those located within the GTPase
region; (iii) this risk is 4-fold lower with OPA1 mutations located
within the dynamin domain; (iv) patients with DOA+ phenotypes
have on average a worse visual prognosis compared to patients
with pure DOA; and (v) OPA1 is a highly polymorphic gene but
there is no evidence that certain combination of single nucleotide
polymorphisms are acting as intragenic modiﬁers and inﬂuencing
either disease severity or speciﬁc clinical manifestations (data not
shown).
Conclusions
Although the majority of patients with OPA1 disease have symp-
tomatic optic neuropathy, additional neuromuscular features are
common in patients with OPA1 mutations. There is currently no
deﬁnitive treatment for this disorder, but the fact that these com-
plex phenotypes eventually develop in up to 20% of all mutational
carriers has important implications for clinical management.
Signiﬁcant neurological impairment can easily be overlooked in
patients and simply attributed to their visual failure, but careful
surveillance of at-risk individuals will identify components which
might be amenable to supportive therapy, such as physiotherapy
or anti-spasmodic drugs for those with upper motor neuron invol-
vement, and cochlear implantation which is of proven beneﬁt in
mitochondrial hearing impairment (Sinnathuray et al., 2003;
Chinnery and Grifﬁths, 2006). The heterogeneous multi-system
manifestations seen in DOA+ families and the remarkable variable
penetrance among carriers with the same pathogenic variant
clearly implicate the inﬂuence of secondary modulatory factors
on the phenotypic expression of the ‘primary’ OPA1 mutation.
Identifying these together with the underlying molecular pathways
will be key in dissecting the complex processes leading to tissue-
speciﬁc dysfunction in both pure and syndromal forms of DOA.
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